WO2006022114A1 - 脳腫瘍の検出方法及びそれに用いる脳腫瘍の検出物質、並びに医薬組成物 - Google Patents
脳腫瘍の検出方法及びそれに用いる脳腫瘍の検出物質、並びに医薬組成物 Download PDFInfo
- Publication number
- WO2006022114A1 WO2006022114A1 PCT/JP2005/013955 JP2005013955W WO2006022114A1 WO 2006022114 A1 WO2006022114 A1 WO 2006022114A1 JP 2005013955 W JP2005013955 W JP 2005013955W WO 2006022114 A1 WO2006022114 A1 WO 2006022114A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- brain tumor
- lectin
- a2g2f
- sugar chain
- cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Definitions
- Brain tumor detection method brain tumor detection substance used therefor, and pharmaceutical composition
- the present invention relates to a method for detecting a brain tumor, a substance for detecting a brain tumor used therein, and a pharmaceutical composition.
- sugar chains are bound to many proteins, and sugar chains bound to proteins are used for cell-to-cell recognition, cell adhesion, or infection of viruses or microorganisms to a host. In addition to playing an important role, it is becoming clear that it also acts as a signal for protein transport and a cofactor in the formation of protein three-dimensional structure.
- glycoprotein sugar chains are essential for the functional expression of the glycoprotein.
- the glycoprotein PO in peripheral nervous system myelin functions as an intercellular adhesion factor, and it is known that the cell adhesion activity is lost when modification is made to the sugar chain binding site of this PO. The This means that PO cannot maintain the conformation necessary for adhesion because the sugar chain that existed by supporting the structure of the protein on the cell membrane is lost due to the adhesion activity of the sugar chain. It is considered Natsume.
- glycoprotein sugar chains play an extremely important role in cell-to-cell recognition even in the development of the nervous system and in various other regions. Therefore, the importance of glycoprotein sugar chains is recognized.
- purification of glycoprotein sugar chains requires a huge amount of time, and there is no systematic analysis method for glycoprotein sugar chains expressed on cell surfaces and tissues. The elucidation was not very advanced.
- Patent Document 1 also discloses cancer based on the N-linked sugar chain A3G3F0 of glycoprotein.
- Non-Patent Document 3 shows that the expression of polysialic acid present on nerve cell adhesion molecule (N-CAM) is highly expressed in metastatic lung cancer and ST8Sia II (STX) gene that regulates polysialic acid. It has been reported that there is a correlation between expression and tumor grade.
- N-CAM nerve cell adhesion molecule
- STX ST8Sia II
- Patent Document 1 Japanese Patent Laid-Open No. 2001-289860
- Non-Patent Document 1 Biochem. 129: 537-542, 2001
- Non-Patent Document 2 Anal. Biochem. 267: 336-343, 1999
- Non-Patent Document 3 Cancer Res., 61: 1666-1670, 2001
- brain tumors are diagnosed by diagnostic imaging such as CT scans and nuclear magnetic resonance apparatuses, but the discovery of detection substances that play a role as tumor markers specific to brain tumors has been expected. .
- cell death programmed to actively evoke cells under physiological conditions, without affecting the surrounding cells, cell surface curvature, nuclear chromatin condensation, chromosomal DNA This is a phenomenon in which cells die due to unique morphological abnormalities such as fragmentation. If this can be induced, it is very advantageous in the treatment of diseases such as malignant tumors.
- an object of the present invention is to provide a method for detecting a brain tumor capable of reliably and early detecting a brain tumor, and a brain tumor detection substance used therefor.
- Another object of the present invention is to provide a pharmaceutical composition for inducing apoptosis of brain tumor cells and effectively preventing and treating brain tumors. Means for solving the problem
- Non-patent Document 1 As a result of intensive studies in view of the above problems, it has been reported that the expression pattern of N-linked sugar chains in normal brain tissue is preserved without any difference (Non-patent Document 1). Therefore, when the expression patterns of N-linked sugar chains were compared between normal tissues and glioma cells, some of the N-linked sugar chains of glycoproteins increased in glioma cells. We focused on this and identified that specific N-linked sugar chain. It was also found that the identified N-linked sugar chain A2G2F is not expressed in normal tissues but only in glioma cells. Furthermore, the present inventors have found that a lens bean (LCA) lectin induces apoptosis in glioma cells, and has arrived at the present invention.
- LCDA lens bean
- the method for detecting a brain tumor according to claim 1 of the present invention is characterized in that a brain tumor is detected based on detection of an N-linked sugar chain A2G2F of a glycoprotein.
- the method for detecting a brain tumor according to claim 2 of the present invention uses a lectin having binding specificity for the N-linked sugar chain A2G2F according to claim 1 V. It is characterized by.
- the method for detecting a brain tumor according to claim 3 of the present invention is characterized in that, in claim 2, the lectin force is lentil lectin.
- the method for detecting a brain tumor according to claim 4 of the present invention is described in claim 1.
- the brain tumor is a glioma.
- the brain tumor detection substance according to claim 5 of the present invention is characterized by containing a lectin having binding specificity for the N-linked sugar chain A2G2F of glycoprotein.
- the substance for detecting a brain tumor according to claim 6 of the present invention is the lectin force lentil lectin according to claim 5.
- the pharmaceutical composition according to claim 7 of the present invention is a pharmaceutical composition for inducing apoptosis on brain tumor cells, and is specific for binding to N-linked sugar chain A2G2F of glycoprotein. It contains a lectin having a property as an active ingredient.
- the pharmaceutical composition according to claim 8 of the present invention is characterized in that, in claim 7, it is the lectin force lentil lectin.
- the pharmaceutical composition according to claim 9 of the present invention is characterized in that, in claim 7, the brain tumor cell is a glioma cell.
- the brain tumor can be surely and early. Can be detected. Furthermore, it is useful for the early detection and treatment of brain tumors.
- a brain tumor can be reliably and early using the lectin having binding specificity for the N-linked sugar chain A2G2F. Can be detected. Furthermore, it is useful for the early detection and treatment of brain tumors.
- glioma can be detected using the lentil lectin having binding specificity to the N-linked sugar chain A2G2F. it can. Furthermore, it is useful for the early detection and treatment of glioma.
- glioma can be reliably and early detected based on the N-linked sugar chain A2G2F.
- the sugar chain A2G 2F can detect brain tumors. Further, by using the detection substance of the present invention, a brain tumor can be detected earlier and easily.
- the sugar chain A2G2F Can detect brain tumors. Further, by using the detection substance of the present invention, a brain tumor can be detected earlier and easily.
- the pharmaceutical composition of claim 7 of the present invention since it has a cell growth inhibitory activity based on apoptosis induction, it does not affect surrounding normal cells, and thus does not affect the surrounding normal cells. Since it can selectively inhibit only growth, it is effective in the prevention and treatment of diseases caused by brain tumor cells.
- apoptosis can be selectively induced in brain tumor cells.
- glioma cells can be selectively eliminated by induction of apoptosis.
- FIG. 1 is a two-dimensional map of mannose units versus glucose units of a standard sugar chain.
- FIG. 2 is a diagram showing a structural formula of a sugar chain.
- GluNAc is an abbreviation for N-acetyltilcosamine, Man for mannose, Gal for galactose, and Fuc for fucose.
- the meaning of each symbol in the structural formula is as follows: An: number of GlcNAc antennas bound to M3 sugar chain structure, Gn: number of galactose residues attached to non-reducing ends, F: One with fucose bound to GluNAc residue at the reducing end, FO: ⁇ 1-3 fucose bound outside GlcNAc, ⁇ : One with GlcNAc bound to mannose in the middle of sugar chain structure.
- FIG. 3 is a reverse phase HPLC elution pattern diagram in Example 1 of the present invention.
- A shows normal tissue and B shows glioblastoma.
- the numbers described in the peaks in the figure correspond to the sugar chain numbers described in FIGS.
- FIG. 4 is a photomicrograph showing the results of immunohistochemical staining in Example 2 of the present invention.
- A shows glioma cell line
- B shows glioblastoma tissue.
- FIG. 5 is a graph showing the results of average survival rate of U251, T98G, ON 12 cells when LCA lectin was added in Example 3 of the present invention.
- FIG. 6 Chromatin aggregation of apoptotic cells in Example 3 of the present invention was observed with a fluorescence microscope. It is a microscope picture which shows the result observed below. A shows no LCA lectin added, B shows LCA lectin added.
- FIG. 7 is a graph showing the detection results of hypodiploid DNA by flow cytometry in Example 3 of the present invention.
- A shows no LCA lectin added
- B shows LCA lectin added.
- FIG. 8 is a graph showing the results of detection of apoptotic cells by flow cytometry using the MEBSTAIN apoptosis kit in Example 3 of the present invention.
- A shows no LCA lectin added
- B shows LCA lectin added.
- FIG. 9 is a graph showing the results of detection of active caspase-13 by flow cytometry in Example 3 of the present invention.
- A shows T98G cells
- B shows U251 cells
- C shows ON12 cells.
- A2G2F as used in the present invention is a glycoprotein sugar chain (Gal jS 1, 4-GlcNA C j 8 1, 2-Man al, 3-) (Gal jS 1, 4 GlcNAc jS 1, 2-Man al , 6—) Man jS 1, 4 GlcNAc jS 1, 4- (Fucal, 6—) GlcNAc, and the meaning of each symbol A2G2F is as follows.
- An Number of GlcNAc antennas that bind to the M3 sugar chain structure
- Gn Number of galactose residues attached to the non-reducing end
- F Fucose attached to the GluNAc residue at the reducing end.
- the brain tumor that can be detected by the detection method of the present invention is a tumor that occurs in a tissue inside the skull, such as the brain and surrounding tissues of the brain, And “metastatic brain tumor” in which cancers of other organs metastasize to the brain.
- Examples of primary brain tumors include glioma, which accounts for about 30% of primary brain tumors, and the most aggressive malignant glioblastoma of glioma.
- an N-linked sugar chain of an isolated brain tissue is analyzed by a glycoprotein sugar chain system using HPLC, and the N-linked sugar chain of a glycoprotein peculiar to a brain tumor is analyzed.
- This is a method for detecting a brain tumor based on the detection of A2G2F.
- a method for detecting a brain tumor using a lectin having binding specificity to the N-linked sugar chain A2G2F It is.
- the lectin used in the method for detecting a brain tumor of the present invention is a substance having a specific binding activity to sugar among proteins or glycoproteins present in a plant 'animal' microorganism.
- a lectin used in the method for detecting a brain tumor of the present invention for example, a lentil (LCA) lens lectin is preferable.
- This lentil lectin is known to specifically bind to a-Fuc bound to the C-6 position of the GlcNAc residue of the sugar chain (Asn-type (N-type) sugar chain) bound to the asparagine of the polypeptide chain. It has been.
- fucosylated ⁇ 1-6GlcNAc structure that specifically binds LCA lectin with only A2G2F in a sugar chain structure of 0.1% or more.
- glioma can be detected with high accuracy, and lectin (LCA lectin) having binding specificity for A2G2F can be used for glioma or glioblastoma. Can be detected earlier and more easily.
- lectin LCA lectin
- brain tumors such as glioma and glioblastoma can be detected earlier and more easily by using an antibody that specifically recognizes A2G2F!
- the brain tumor detection substance of the present invention is not particularly limited as long as it contains a lectin that specifically binds to the N-linked sugar chain A2G2F of the glycoprotein.
- lectins that specifically bind to the N-linked sugar chain A2G2F include LCA lectins.
- the brain tumor detection substance of the present invention may be an antibody that specifically recognizes the N-linked sugar chain A2G2F.
- antibodies that recognize A2G2F include monoclonal antibodies and polyclonal antibodies. These antibodies can be produced by administering A2G2F sugar chains to experimental animals using conventional protocols.
- a lectin that specifically binds A2G2F or an antibody that specifically recognizes A2G2F can be labeled with a chemical fluorescent reagent, a radioisotope, or the like.
- chemical fluorescent reagents include fluorescein, rhodamine and luminol
- radioactive isotopes include 3H, 14C, 35S, 33P, 32P and 1251.
- A2G2F can be used as a brain tumor marker, for example, by diagnostic imaging using conventional CT scans, nuclear magnetic resonance devices, etc. By using the methods in combination, it is possible to detect or diagnose a brain tumor with high accuracy at an early stage and with certainty.
- the pharmaceutical composition of the present invention is a pharmaceutical composition for inducing apoptosis of brain tumor cells, and comprises, as an active ingredient, a lectin having binding specificity for N-linked sugar chain A2G2F of glycoprotein.
- the lectin used as the active ingredient of the present invention is a substance having specific binding activity to sugar among proteins or glycoproteins present in plant 'animal' microorganisms.
- the lectin used as the active ingredient of the present invention is preferably a lentil (LCA) lectin.
- the pharmaceutical composition of the present invention may be used as a pharmaceutical composition for inducing apoptosis in combination with a pharmaceutical agent or a pharmaceutical ingredient depending on the purpose of use.
- the pharmaceutical agent used in combination include an anticancer agent, an antiviral agent, and an antiautoimmune disease agent.
- the pharmaceutical composition of the present invention is effective in preventing and treating diseases caused by brain tumor cells by encapsulating a pharmaceutical agent such as an anticancer agent in the pharmaceutical composition of the present invention to concentrate the drug locally.
- the pharmaceutical composition of the present invention is used in various dosage forms conventionally used in this field as a pharmaceutical preparation.
- it can be formulated in the form of powder, tablets, pills, solutions, suspensions, emulsions, granules, capsules, injections (solutions, suspensions, etc.), and solubilizing agents as desired
- Additives commonly used in injection solutions such as buffers, tonicity agents, stabilizers, preservatives, soothing agents, fillers, extenders, binders, moisturizers, disintegrants, surface active agents, Or an excipient
- the pharmaceutical composition of the present invention is administered orally or parenterally. The dose varies depending on the degree of brain tumor to be treated and is not particularly limited.
- the present invention is not limited to the above-described embodiment.
- the above embodiment is merely an example, and has any configuration that is substantially the same as the technical idea described in the claims of the present invention and that exhibits the same operational effects. Are also included in the technical scope of the present invention.
- Glycoprotein glycan analysis was performed using 3 normal brain tissues, 15 glioblastoma tissues, and 3 glioma cell lines.
- Fifteen glioblastoma tissues were collected at Niigata University Hospital from patients with glioblastoma (see Table 1) and informed consent was collected.
- PBS NaCl 8g
- KH PO 0.24g is dissolved in 1 liter of water and adjusted to pH 7.4
- the prepared one was used.
- the brain tissue was homogenized in 9 volumes of cold acetone using a polytron homogenizer, left at -20 ° C for 60 minutes, and then centrifuged at 4 ° C and 8000G for 20 minutes. After removing the supernatant, the same operation was performed again, and then the precipitate was lyophilized to obtain a sample.
- a sample with a dry weight of 2 mg was subjected to hydrazine decomposition using GlycoPrep TM 1000 (Oxford Glycosystems, Oxford, UK) to cleave the sugar chain from the protein.
- the isolated sugar chain was photolabeled with pyridylaminoi using GlycoTag TM (Takara, Tokyo, Japan) and then neuraminidase (from Arthrobacter ureafaciens, Nacalai Tesque, Kyoto, Japan). ) Treated the sugar chain to cleave the sialic acid in the side chain. As a result of the cleavage of the charged sialic acid, a neutral sugar chain present in the brain tissue of the specimen could be obtained.
- solvent B was increased linearly to 19% 1 minute after injection and 57% 35 minutes later.
- Fluorescently labeled sugar chains that also elute here are detected at an excitation wavelength of 310 nm and a detection wavelength of 380 nm, and standard sugar chains (PA-sugar chains M2A, M3B, M4B, M5A, M6B, M7A, M8A, M9A (Takara, Tokyo , Japan)), fractions M2 to M10 were fractionated.
- the M10 elution time was set as M9A elution time + 1.5 minutes.
- the flow rate is 1.5 ml / min, the column temperature is 30 ° C, solvent C is 0.1 M ammonium acetate buffer (pH 4.0), solvent 0 Assuming that 0.5% 1-butanol is added to the solvent, start with a solvent C: solvent D ratio of 94: 6, and then add solvent D to 80% 45 minutes after loading the sample. Increased linearly. Fluorescently labeled sugar chains that also elute here were detected at an excitation wavelength of 320 nm and a detection wavelength of 400 nm, and the elution patterns were compared and examined by the following procedure to determine the structure and content of sugar chains in the sample.
- a glucose oligomer standard sugar chain to which 3 to 22 bud sugars were bound
- GU glucose unit
- the sugar chain contained in that peak is collected, and this is again input to normal-phase HPLC.
- this time calculate the mannose unit (MU) and use the two indicators GU and MU for each peak observed in reversed-phase HPLC to indicate GU on the horizontal axis and MU on the vertical axis.
- FIG. 1 is a two-dimensional map of standard sugar chains, where the horizontal axis shows glucose unit values and the vertical axis shows mannose unit values.
- Figure 2 shows the sugar chain structural formulas with numbers plotted on the graph in Fig. 1.
- number 1 is A0G0F
- 2 is A2G1F0
- 3 is A2G1F0
- 5 ⁇ to A2G2F 6 ⁇ to A3G3, 7 ⁇ to 2, 2, 8 ⁇ to M2B
- 9 ⁇ to 3 ⁇ 10 11 indicates M5A
- 12 indicates M6B
- 13 indicates M7A
- 14 indicates M7B
- 15 indicates M8A
- 16 indicates M9A.
- FIG. 3 shows the elution patterns of all fractions (M2 to M11) in reversed-phase HP LC analysis of N-linked sugar chains of human normal brain tissue (A) and glioblastoma tissue (B). Peak 5 is observed only in the M6 and M7 fractions of glioblastoma tissue (B) and is confirmed in human normal brain tissue (A). It was not recognized. This peak 5 was identified as sugar chain A2G2F by the two-dimensional map shown in FIG. This indicates that the glycan A2G2F is a glycoma-specific glycan that is not expressed in normal brain tissue but is expressed only in glioma cells.
- A2G2F was found in a glioblastoma cell line and a glioblastoma tissue, which was a powerful force not found in normal brain tissue (P 0.01).
- A2G2F contained 2.9 ⁇ 1.93% in glioblastoma tissues and 5.60 ⁇ 1.14% in glioma cell lines.
- ion exchange HPLC was performed, and the A2G2F sialic acid ratio was found to be 62.20% and 56.19%.
- A2G2 was found in 12.66 ⁇ 8.3.3% in nephron glioblastoma thread and tissue, and was significantly higher than 2.78 ⁇ 0.60% in normal brain tissue.
- A3G3 was found in 1.00 ⁇ 0.79% in glioblastoma tissue and 3.51 ⁇ 2.13% in glioma cell lines.
- the hyperbranched sugar chains found in lung cancer and hepatocellular carcinoma were not found in the glioblastoma tissue.
- FIG. Figure 4-A shows immunohistochemical staining of a glioma cell line.
- FIG. 4A shows immunohistochemical staining of glioblastoma tissue.
- Fig. 4A shows very strongly with LCA
- Fig. 4-B shows glioblastoma tissues.
- LCA lectin that specifically binds to A2G2F Specific binding to woven and glioma cell lines was found. Therefore, it is possible to detect a brain tumor using a lectin labeled with a fluorescent reagent having binding specificity for A2G2F expressed only in a brain tumor.
- T98G Green Cell Bank, Tsukuba, Japan
- ON-12 glioma cell lines cultured from glioblastoma patient tissue with 10% FCS, 50 mM 2-mercaptoeta norole, 10 mM Cultured in MEM medium (Invitrogen, Tokyo Japan) containing Pes (HepesKpH 7.4), 2 mM glutamine, lOOUZml pecillin, 100 g / ml streptomycin was used as a sample.
- the TdT (terminal deoxynucleotidyl transferase) reaction solution is stirred for 30 1 hours against the cell sediment and allowed to react at 37 ° C for 1 hour. It was.
- the cell sediment was suspended in 5001 PBSZO. 2% BSA and measured by flow cytometry.
- Intracellular caspase 3 was examined using FITC-conjugated rabbit anti-active caspase 3 monoclonal antibody (BD PharMingen, Tokyo, Japan). Specifically, 25 gZml of LCA lectin was added to each cell of U251, T98G, ON-12 and cultured for more than 24 hours to recover the cell sediment, and then FITC-conjugated rabbit anti-active caspase 3 monochrome. The antibody (BD PharMingen, Tokyo, Japan) was stirred for 20 hours and reacted at 4 ° C for 1 hour. Next, after washing with PBS / 0.2% BSA, the cell pellet was suspended in 5001 PBS / 0.2% BSA and measured by flow cytometry.
- BD PharMingen FITC-conjugated rabbit anti-active caspase 3 monoclonal antibody
- FIG. 5 is a graph showing the results of average survival of U251, T98G, ON-12 cells when LCA lectin was added to U251, T98G, ON-12 cells, respectively.
- U251, T98G, ON-12 cells were suppressed in their cell growth ability in a concentration-dependent manner by LCA lectin supplementation.
- FIG. 6 shows that T98G cells were not supplemented with LCA lectin! /, (A) and LCA lectin added (B), and then used Hoechst 33342 fluorescent dye.
- 5 is a photomicrograph showing the results of observation of chromatin aggregation of apoptotic cells under a fluorescence microscope. In the cells to which LCA lectin in Fig. 6-B was added, dyes gathered at the chromatin aggregates (indicated by arrows) and strong blue fluorescent staining was observed. These results indicate that apoptosis is induced by LCA lectin, since chromatin aggregation is one of the most characteristic morphological changes associated with apoptosis.
- FIG. 7 is a graph showing the detection results of hypodiploid DNA by flow cytometry.
- Figure 7-A is a typical DNA histogram of a control nucleus without T98G cells supplemented with LCA lectin
- Figure 7-B is cultured with T98G cells supplemented with LCA lectin. It is a DNA histogram of the collected cells. As shown in Fig. 7, when hypodiploid DNA was examined by nuclear staining, it was 0.29% in T98G cells without treatment, but 31.99% when LCA lectin was added. An increase in hypodiploid DNA due to cocoon was observed.
- FIG. 8 is a graph showing the detection results of apoptotic cells by flow cytometry using MEBSTAIN apoptosis kit.
- the LCA lectin of T98G cells was not added (Fig. 8-A).
- the supplemented product Fig. 8-B
- FIG. 9 is a graph showing the results of detection of active caspase-13 by flow cytometry.
- Figure 9—A, B, and C show the detection results of caspase-3 positive cells in T98G, U251, and ON12 cells, respectively.
- the solid line in the figure indicates that the LCA lectin is added, and the broken line indicates that the LCA lectin is not added.
- the cells of T98G, U251, and ON12 were 36. 78%, 23. 03%, and 20. 86% when LCA lectin was added, respectively, compared to those without LCA lectin.
- An increase in activated caspase-3 was observed.
- LCA lectin induced apoptosis in glioma cells, and it became clear that it was caspase pathway-dependent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006531442A JP4852703B2 (ja) | 2004-08-27 | 2005-07-29 | 脳腫瘍の検出方法及びそれに用いる脳腫瘍の検出物質 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004247849 | 2004-08-27 | ||
JP2004-247849 | 2004-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006022114A1 true WO2006022114A1 (ja) | 2006-03-02 |
Family
ID=35967333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/013955 WO2006022114A1 (ja) | 2004-08-27 | 2005-07-29 | 脳腫瘍の検出方法及びそれに用いる脳腫瘍の検出物質、並びに医薬組成物 |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP4852703B2 (ja) |
WO (1) | WO2006022114A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008096790A1 (ja) * | 2007-02-07 | 2008-08-14 | Galpharma Co., Ltd. | 腫瘍マーカー糖鎖の解析及び利用 |
JP2008209261A (ja) * | 2007-02-27 | 2008-09-11 | J-Oil Mills Inc | α1,6フコース糖鎖の検出および分別方法 |
WO2016021729A1 (ja) * | 2014-08-08 | 2016-02-11 | 国立大学法人北海道大学 | グリオーマの診断マーカー、判別方法、診断方法、糖鎖マーカーを検出する方法及び糖鎖マーカー |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101868042B1 (ko) * | 2016-08-08 | 2018-06-18 | 한국과학기술연구원 | 뇌종양 진단을 위한 당단백질을 검출하는 방법, 및 이에 이용되는 조성물 또는 키트 |
JP2022539494A (ja) | 2019-07-09 | 2022-09-12 | ユニケム ラボラトリーズ リミテッド | 組換えタンパク質の安定な製剤 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004231555A (ja) * | 2003-01-29 | 2004-08-19 | Tokyoto Koreisha Kenkyu Fukushi Shinko Zaidan | グリオーマ治療剤及び細胞分化誘導剤または増殖抑制剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001289860A (ja) * | 2000-04-07 | 2001-10-19 | Hiromi Wada | 癌検出方法及びそれに用いる癌検出物質 |
-
2005
- 2005-07-29 WO PCT/JP2005/013955 patent/WO2006022114A1/ja active Application Filing
- 2005-07-29 JP JP2006531442A patent/JP4852703B2/ja active Active
-
2011
- 2011-03-14 JP JP2011055200A patent/JP5158577B2/ja not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004231555A (ja) * | 2003-01-29 | 2004-08-19 | Tokyoto Koreisha Kenkyu Fukushi Shinko Zaidan | グリオーマ治療剤及び細胞分化誘導剤または増殖抑制剤 |
Non-Patent Citations (1)
Title |
---|
FUJIMOTO ET AL: "Systematic Analysis of N-Linked Sugar Chains from Whole Tissue Employing Partial Automation", ANALYTICAL BIOCHEMISTRY, vol. 267, no. 2, 15 February 1999 (1999-02-15), pages 336 - 343, XP002993791 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008096790A1 (ja) * | 2007-02-07 | 2008-08-14 | Galpharma Co., Ltd. | 腫瘍マーカー糖鎖の解析及び利用 |
JP2008209261A (ja) * | 2007-02-27 | 2008-09-11 | J-Oil Mills Inc | α1,6フコース糖鎖の検出および分別方法 |
WO2016021729A1 (ja) * | 2014-08-08 | 2016-02-11 | 国立大学法人北海道大学 | グリオーマの診断マーカー、判別方法、診断方法、糖鎖マーカーを検出する方法及び糖鎖マーカー |
Also Published As
Publication number | Publication date |
---|---|
JP5158577B2 (ja) | 2013-03-06 |
JPWO2006022114A1 (ja) | 2008-05-08 |
JP2011126907A (ja) | 2011-06-30 |
JP4852703B2 (ja) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dan et al. | Development and applications of lectins as biological tools in biomedical research | |
Yu et al. | Functional glycomic analysis of human milk glycans reveals the presence of virus receptors and embryonic stem cell biomarkers | |
Su et al. | Cell surface nucleolin facilitates enterovirus 71 binding and infection | |
JP5158577B2 (ja) | 医薬組成物 | |
US20170240632A1 (en) | Compositions and methods for identifying and treating cachexia or pre-cachexia | |
US20210322513A1 (en) | Method for detecting cancer cells, reagent for introducing substance into cancer cells, and composition for treating cancer | |
US20140274768A1 (en) | Glycoforms of MUC5AC and Endorepellin and Biomarkers for Mucinous Pancreatic Cysts | |
KR20230009999A (ko) | 루테리알의 형태특성을 이용한 질병의 진단방법 | |
Ye et al. | p53 deacetylation alleviates calcium oxalate deposition-induced renal fibrosis by inhibiting ferroptosis | |
WO2021243932A1 (zh) | 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用 | |
Wu et al. | Osteoclast-derived apoptotic bodies inhibit naive CD8+ T cell activation via Siglec15, promoting breast cancer secondary metastasis | |
US20200340996A1 (en) | Methods for detecting and for treating pancreatic cancer | |
Tsuchiya et al. | Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines | |
Gill et al. | Solitary plasmacytoma of skull: a rare cytological diagnosis | |
EP3998340A1 (en) | Aptamer specifically binding to kras protein and method for using same | |
CN114854815A (zh) | 巨噬细胞迁移小体作为脑淀粉样血管病治疗靶标的应用 | |
JP7062063B2 (ja) | 前立腺がんに特異的な糖鎖、及びこれを用いた検査方法 | |
JP2007205777A (ja) | 変形性関節症の診断支援方法 | |
Gornowicz et al. | Mucin 1 as a molecular target of a novel diisoquinoline derivative combined with anti-MUC1 antibody in AGS gastric cancer cells | |
Mane et al. | Lectin as an Anticancer Therapeutic Agent | |
CN116655807A (zh) | 一种特异性靶向蛋白拮抗多肽、其制备方法和应用 | |
Krycia | Isolation, Purification, and Characterization of a New Mannose-Binding Plant Lectin That Recognizes Fungal Antigens | |
JP2009098108A (ja) | 糖鎖を持つ物質の精製方法及びその利用 | |
Pham | Investigating Sialic Acid Deficiency on Promoting Renal Thrombosis | |
Murali | TMEM165: Novel Golgi Antiporter Involved in Breast Cancer Progression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006531442 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |